Loading...
Viridian Therapeutics Q1 2025 Earnings Report
Viridian Therapeutics reported its financial results for the first quarter ended March 31, 2025, highlighting progress in its clinical programs and a strong cash position.
Key Takeaways
Viridian Therapeutics reported a net loss of $86.912 million for the first quarter of 2025, with total revenue of $0.072 million. The company maintained a strong cash position of $636.6 million, which is expected to fund operations into the second half of 2027. Research and development expenses significantly increased compared to the prior year, reflecting expanded clinical trial activities.
Total revenue for Q1 2025 was $0.072 million, consistent with the previous year.
Net loss for Q1 2025 was $86.912 million, compared to $48.542 million in Q1 2024.
Research and development expenses increased to $76.835 million in Q1 2025 from $40.944 million in Q1 2024, driven by increased clinical trial activities.
The company's cash position stood at $636.6 million as of March 31, 2025, providing a runway into the second half of 2027.
Viridian Therapeutics
Viridian Therapeutics
Viridian Therapeutics Revenue by Segment
Revenue by Segment
Collaboration Revenue - related party Revenue
CapyFin.com Forward Guidance
Viridian Therapeutics is on track with key milestones for its clinical programs, including BLA submission for veligrotug and topline data for VRDN-003, and expects its strong cash position to support operations into the second half of 2027.
Positive Outlook
- BLA submission for veligrotug on track for second half 2025, with potential U.S. launch in 2026.
- REVEAL-1 and REVEAL-2 (VRDN-003) phase 3 clinical trials on track for topline data in first half of 2026.
- VRDN-006 clinical data in healthy volunteers on track for third quarter 2025.
- VRDN-008 IND submission on track for year-end 2025.
- Strong cash position of $636.6 million supports cash runway into the second half of 2027.
Challenges Ahead
- Anticipated U.S. launch of veligrotug is dependent on BLA approval.
- Topline data for VRDN-003 is still a year away, in the first half of 2026.
- Commercial launch of VRDN-003 is planned by year-end 2026, contingent on BLA submission and approval.
- IND submission for VRDN-008 is still pending and on track for year-end 2025.
- The company's success is dependent on the successful development and commercialization of its product candidates.